What You Need to Know Ahead of Eli Lilly's Earnings Release
What You Need to Know Ahead of Eli Lilly's Earnings Release.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a leading pharmaceutical company that sells Trulicity, Verzenio and Taltz drugs. The company discovers, develops, and markets human pharmaceuticals. With a market cap of $1.1 trillion, LLY's products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products. The pharmaceutical giant is expected to announce its fiscal second-quarter earnings for 2026 before the market opens on Wednesday, Aug. 5.
Ahead of the event, analysts expect LLY to report a profit of $7.47 per share on a diluted basis, up 18.4% from $6.31 per share in the year-ago quarter. The company has consistently surpassed Wall Street's EPS estimates in its last four quarterly reports.
PayPal Says a $53 Billion Takeover Offer from Stripe Undervalues It. How to Play PYPL Stock Here.
Billionaire Jeff Bezos Called Amazon's Customer Service to Prove a Point But Waited in Silence for More Than 10 Minutes — 'It Was Really Long'
Micron Stock Is Near Bear-Market Territory. Here's Why ASML's Guidance Says Buy the Dip.
For the full year, analysts expect LLY to report EPS of $34.55, up 42.7% from $24.21 in fiscal 2025. Its EPS is expected to rise 30.5% year over year to $45.10 in fiscal 2027.
LLY stock has outperformed the S&P 500 Index's ($SPX) 19.1% gains over the past 52 weeks, with shares up 54.2% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF's (XLV) 22.2% returns over the same time frame.
LLY outperformed on multiple catalysts. The EMA committee backed Jaypirca for chronic lymphocytic leukemia, moving it closer to EU approval. Medicare's new GLP-1 Bridge program will offer Zepbound and Foundayo for a $50 copay starting July 2026, broadening access. Lilly also announced nearly $4 billion in vaccine deals to expand into shingles, EBV, and antibacterial vaccines. Strong demand for Mounjaro and Zepbound, which generated $12.8 billion, plus early uptake of newly approved Foundayo, further reinforced the bullish outlook.
Analysts' consensus opinion on LLY stock is bullish, with a "Strong Buy" rating overall. Out of 29 analysts covering the stock, 22 advise a "Strong Buy" rating, three suggest a "Moderate Buy," and four give a "Hold." LLY's average analyst price target is $1,292.93, indicating a potential upside of 10% from the current levels.
On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Sinergia Empresarial continuará el seguimiento de esta información sobre what You Need to Know Ahead of Eli Lilly's Earnings Release y ampliará la cobertura conforme se confirmen nuevos elementos relevantes para el ecosistema empresarial.
